Table 2

Model input-data
Base-case DSA PSA
HZ PHN HZ PHN
Epidemiology[21]
Age-group Cases/1,000 PY % of HZ-cases 95% CI (Cases/1,000 PY) 95% CI (% of HZ-cases) Triangular
50–59 6.56 3.38 6.12–7.01 2.15–4.61
60–69 9.19 4.92 8.68–9.71 3.73–6.11
70–79 11.24 7.85 11.66–11.82 6.48–9.23
>80 12.76 7.8 11.92–13.61 6.05–9.55
Vaccine efficacy (%)[29,30,50,51]
Age-group 95% CI 95% CI Beta
50–59 69.8 65.7* 54.1–80.6 20.4*–86.7*
60–64 65.4 65.7 55–70.9 20.4–86.7
65–69 62.58 65.7 55–70.9 20.4–86.7
70–74 43.74 66.8 25–48.1 43.3–81.3
75–79 36.51 66.8 25–48.1 43.3–81.3
80–84 20.09 66.8 25–48.1 43.3–81.3
>85 13.22 66.8 25–48.1 43.3–81.3
EQ-5D utilitiesª[14]
Age-group 95% CI 95% CI Beta
50–60 0.68 0.725 0.61–0.745 0.63–0.815
61–70 0.6 0.68 0.525–0.67 0.605–0.76
>70 0.62 0.64 0.550.69 0.57–0.705
Treatment costs per case (€)[21]
Perspectives/Age-group Payer Societal Payer Societal Payer 95% CI Societal 95% CI Payer 95% CI Societal 95% CI Gamma
50–59 193 570 872 1,339 148–245 495–651 289–1,940 436–3,065
60–69 226 338 1,349 2,137 179–270 281–397 714–2,125 975–3,625
70–79 203 214 1,172 1,218 159–252 169–263 717–1,785 750–1,863
>80 320 331 642 676 249–394 259–408 251–1,157 270–1,207
Background mortality [probability (%) p.a.]***[48] HZ related mortality [deaths/100,000 PY]***[22]
Age-group
50–59 0.7 0.02
60–69 1.5 0.09
70–79 3.9 0.42
80–89 11 2.53
90–99 26.2 3.86
100+ 56.8 3.86
Other input parameter
Base-case DSA [lower/higher value] PSA
Vaccine Price/dose (€)[59] 140.48 70.24 210.72 Normal
Vaccine administration costs (€)** 7 5.20 10.81 Normal
Discount rate (% p.a.) 3 0 10
Waning immunity rate (% p.a.)[56] 8.3 0 20 Beta
Coverage (%) assumption 20 - -
HZ susceptibility**** (%)[2] 100 - -
EQ-5D utilities for healthy individuals (age in years) 1(all ages) 0.859b (41–60) 0.7684b (61+)

DSA Deterministic Sensitivity Analysis, PSA Probabilistic Sensitivity Analysis displays the age related probability distribution of respective input-data used in Monte Carlo simulations, CI confidence interval, *value adopted from age 60; **vaccine administration costs adopted from pneumococcal vaccination (adjusted from different regional values); ***Values adjusted to table’s age-groups; ****All individuals in the model were susceptible for developing HZ due to high seroprevalence of varicella-zoster virus in the German population; ªAdjusted from Drolet et al. [14]; bGender unspecific values adjusted from linear model in Hinz et al. [61]; , Euro in 2010 price levels; PY persons per year.

Ultsch et al.

Ultsch et al. BMC Health Services Research 2013 13:359   doi:10.1186/1472-6963-13-359

Open Data